Enovis Q3 revenue $384M (+7% organic), adj EPS $0.59 (+34% YoY), guides FY adj EPS $2.20-$2.25

Enovis CORP

2022-Q3 EPS reported $0.46 revenue$1,154,388,000

Reconstructive segment revenue $127M (+15% organic); Prevention & Recovery $257M (+4% organic).
Reported net loss from continuing ops $(66)M ($(1.22)/diluted share); adjusted EPS grew to $0.59.
Adjusted EBITDA $57M (14.9% of sales); core margins improved 40 bps despite inflation.
FY 2022 outlook: organic growth ~6.5%, total sales growth ~10%, adj. EBITDA $235-$240M.
Launched EMPOWR 3D Knee in Europe and two connected bracing products for Motion iQ platform.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Enovis CORP reported third quarter 2022 results: revenue $384 million, net income $(66) million, EPS $(1.22) per diluted share.

Period: third quarter 2022
Revenue: $384 million
Net income: $(66) million
EPS: $(1.22) per diluted share
Result: reported results

Exact text from the filing

Enovis’ third quarter net sales of $384 million were 7% higher than the prior year third quarter on both reported and organic bases. Enovis Reconstructive segment revenue of $127 million reflected 15% organic growth, and its Prevention and Recovery segment revenue of $257 million reflected 4% organic growth. The Company reported third quarter 2022 net loss from continuing operations of $(66) million, or $(1.22) per diluted share

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Enovis CORP filing history →

Source: SEC EDGAR

accession 0001420800-22-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.